article · PLoS ONE
The Johnson & Johnson COVID-19 vaccine was associated with short-term RBS fluctuations and a sustained increase in HbA1c levels in T2DM patients. These findings highlight the need for personalized glycemic monitoring post-vaccination. Despite these metabolic variations, the vaccine's protective role against severe COVID-19 outweighs transient glycemic disturbances. Incorporating vaccination efforts into comprehensive diabetes management is crucial, and additional studies are warranted to investigate the underlying biological mechanisms.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1371/journal.pone.0340457
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
